OraSure Technologies

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OraSure Technologies excels in Q4 2022, eyes strategic partnerships for growth

OraSure Technologies showcased robust financial performance, operational efficiency, and strategic partnerships in Q4 2022.
While facing challenges in margin structure and international mix, the company is focused on core growth and cost-saving initiatives.
Opportunities lie in business unit consolidation, product innovation, and strategic partnerships for future growth and profitability.

OraSure Technologies reports record Q1 revenue, focuses on growth

OraSure Technologies delivered strong Q1 results with record revenue and improved margins, driven by IntelliSwab sales. While facing challenges in product diversification and cost management, the company's focus on efficiency and innovation presents growth opportunities. Strategic partnerships and a solid financial position further support its growth trajectory.

OraSure Technologies reports robust Q2 earnings, eyes growth opportunities ahead

OraSure Technologies delivered strong financial performance in Q2 2023, with revenue growth, operating cash flow, and strategic advancements across key business segments.
While facing challenges in margin improvement and revenue forecasting, the company's focus on cost reductions, operational efficiencies, and growth strategies positions it for long-term success.
By leveraging strengths in core business areas, collaborations, and innovation, OraSure is well-positioned to capitalize on opportunities for accelerated growth and market expansion.

OraSure Technologies excels in Q3 with revenue growth and strategic milestones

OraSure Technologies demonstrated strong financial performance and operational efficiency in Q3 2023, with notable revenue growth and cash flow generation.
While facing challenges in margin moderation and operating expenses, the company's strategic focus on innovation and partnerships presents growth opportunities.
Overall, OraSure's successful milestones, revenue diversification, and cost management efforts position it for continued growth and market leadership.

OraSure Technologies posts strong Q4 results amidst market challenges

OraSure Technologies demonstrated robust financial performance in Q4 2023, driven by revenue diversification and strategic cost-saving initiatives.
While facing challenges in muted core revenue growth for Q1 2024, the company remains confident in its long-term growth prospects.
Strategic partnerships and investments present opportunities for revenue expansion and market penetration in key segments.

OraSure Technologies surpasses Q1 revenue targets, eyes operational breakeven

OraSure Technologies delivered strong financial performance in Q1, exceeding revenue guidance and showcasing core revenue strength.
While facing challenges in business transitions and cost management, the company's strategic focus on efficiency and growth presents opportunities.
With a solid cash position, key partnerships, and a clear roadmap to breakeven in operating cash flow, OraSure is poised for future success.

OraSure Technologies reports robust Q2 results and eyes global expansion

OraSure Technologies delivered strong Q2 financial results with revenue near guidance ranges and operational improvements.
The company faces challenges in cost restructuring and gross margin outlook but sees growth opportunities in new products and partnerships.
International revenue growth, strategic partnerships, and product extensions position OraSure for future success and market expansion.

OraSure Technologies reports stable Q3 performance and eyes growth

OraSure Technologies navigated Q3 with stable financial performance, focusing on core revenue growth and strategic business realignment.
The company's emphasis on innovation, new market entry, and financial strength positions it well for future growth and market expansion.
While challenges like revenue decline and business transitions exist, OraSure Technologies is proactively addressing them to capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

BETHLEHEM, Pa., June  10, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $629,217 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to develop an Enzyme-Linked Immunosorbent Assay (ELISA) for the detection of human anti-SARS-CoV-2 antibodies in oral fluid specimens. Currently, there are no oral fluid-based COVID antibody tests available with automated assays. 

OraSure Technologies Receives BARDA Funding for Coronavirus Antibody ELISA Using Oral Fluid Samples

The number of EUAs utilizing OraSure’s saliva collection products continues to grow The number of EUAs utilizing OraSure’s saliva collection products continues to grow

OraSure’s Oragene®•Dx included in EUA allowing at-home saliva collection for use with Phosphorus SARS-CoV-2 test

BETHLEHEM, Pa., June  03, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced the full exercise by the underwriters of their option to purchase an additional 1,200,000 shares of its common stock in connection with the Company’s previously announced offering that priced on June 2, 2020.  In total, 9,200,000 shares of common stock of the Company are being sold in the offering. With the exercise by the underwriters of their option to purchase such additional shares, after the underwriting discount and estimated offering expenses, OraSure expects to receive net proceeds of approximately $94.9 million. The offering is expected to close on June 5, 2020, subject to customary closing conditions. J.P. Morgan Securities LLC, Citigroup and Evercore Group L.L.C. are acting as joint book‑running managers of the offering and as representatives of the underwriters. UBS Investment Bank and Raymond James & Associates, Inc. are acting as co-managers of the offering.

OraSure Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares of Common Stock

BETHLEHEM, Pa., June  02, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced the pricing of an underwritten offering of 8,000,000 shares of its common stock at a price of $11.00 per share. After the underwriting discount and estimated offering expenses, OraSure expects to receive net proceeds of approximately $82.48 million. In addition, OraSure has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 of shares of its common stock. The offering is expected to close on June 5, 2020, subject to customary closing conditions. J.P. Morgan Securities LLC, Citigroup and Evercore Group L.L.C. are acting as joint book-running managers of the offering and as representatives of the underwriters. UBS Investment Bank and Raymond James & Associates, Inc. are acting as co-managers of the offering.

OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock

BETHLEHEM, Pa., June  01, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced it has commenced an underwritten public offering of 8,000,000 shares of its common stock. J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Evercore Group L.L.C. are acting as joint book running managers of the offering and as representatives of the underwriters. UBS Investment Bank and Raymond James & Associates, Inc. are acting as co-managers. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.

OraSure Technologies, Inc. Announces Proposed Public Offering of Common Stock

Acquisition strengthens OraSure’s leadership position in HIV field Acquisition strengthens OraSure’s leadership position in HIV field

OraSure Technologies, Inc. Announces Purchase of UrSure, Inc.

BETHLEHEM, Pa., May  29, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the appointment of Lelio Marmora as a member of the Company’s Board of Directors effective June 1, 2020.  Mr. Marmora, the former executive director of Unitaid, will serve as a Class III Director with an initial term expiring at the Company’s 2021 Annual Meeting of Stockholders.  He will also serve on the Audit Committee and Nominating and Corporate Governance Committee of the Board.

OraSure Technologies Appoints Lelio Marmora to Board of Directors

OTTAWA, May  22, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, (NASDAQ: OSUR), announced today that its OMNIgene®·ORAL saliva collection device (OM-505) was included in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to P23 Labs. This EUA permits individuals to self-collect saliva specimens at-home for the detection of SARS-CoV-2.

OraSure’s OMNIgene®·ORAL Kit Included in EUA Granted to P23 Labs for At-Home Collection of  Saliva Samples for SARS-CoV-2 Test

ST. PAUL, Minn. and OAKLAND, Calif., May  22, 2020  (GLOBE NEWSWIRE) -- Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ: OSUR), and Nom Nom™, a direct-to-consumer pet health brand, today announced that Nom Nom has selected Diversigen as their preferred provider for metagenomics and microbiome sequencing and analysis services. Diversigen will also serve as Nom Nom’s central lab for the generation of high quality microbiome data.

Diversigen Inc. Selected by Nom Nom™ as the Preferred Provider for Metagenomics and  Microbiome Sequencing and Analysis Services

All Microbiome Services to be Unified under the Diversigen Brand

OraSure Technologies, Inc. Consolidates Microbiome Services Subsidiaries

OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q1 2020 Results - Earnings Call Transcript

Board Change Also Announced Board Change Also Announced

OraSure Technologies Appoints Lisa Nibauer as Infectious Disease Business Unit Lead

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: OraSure Technologies (OSUR) Q1 Earnings Expected to Decline

Other Board Changes Also Announced Other Board Changes Also Announced

OraSure Technologies Appoints David J. Shulkin, M.D.

BETHLEHEM, Pa., April  06, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $710,310 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), to develop a pan-SARS-coronavirus antigen rapid in-home self-test that uses oral fluid samples.  This support from BARDA will enable OraSure to file for FDA Emergency Use Authorization (EUA) allowing for an in-home self-test to debut into the U.S. market.

OraSure Technologies Receives BARDA Contract for Rapid Oral Fluid Pan-SARS-Coronavirus In-home Self-test

OraSure Technologies (OSUR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

OraSure Technologies (OSUR) in Focus: Stock Moves 7.6% Higher

OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q4 2019 Results - Earnings Call Transcript

OraSure (OSUR) delivered earnings and revenue surprises of -14.29% and 5.60%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Lags Q4 Earnings Estimates

BETHLEHEM, Pa., Dec.  17, 2019  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:  OSUR) today announced that its 2020 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 19, 2020.  The record date for the Meeting will be March 27, 2020.  Only stockholders of record as of the close of business on the record date will be entitled to vote at the 2020 Annual Meeting, or any adjournment(s) or postponement(s) of the Meeting.  This will be a completely virtual meeting, conducted as a live webcast.  Further details regarding the Meeting will be provided at a later date.

OraSure Technologies Announces 2020 Annual Meeting Date

OraSure Technologies Inc. (OSUR) CEO Stephen Tang on Q3 2019 Results - Earnings Call Transcript

OraSure (OSUR) delivered earnings and revenue surprises of 66.67% and -5.13%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Q3 Earnings Surpass Estimates

Acquisition extends OraSure’s leadership position in the microbiome services industry Acquisition extends OraSure’s leadership position in the microbiome services industry

OraSure Technologies, Inc. Announces Purchase of Diversigen

Earnings Preview: OraSure Technologies (OSUR) Q3 Earnings Expected to Decline

BETHLEHEM, Pa., Oct.  28, 2019  (GLOBE NEWSWIRE) -- The Substance Abuse and Mental Health Services Administration (SAMHSA) has published new guidelines, permitting oral fluid drug testing in federally regulated markets. SAMHSA is the agency within the U.S. Department of Health and Human Services focused on reducing the impact of substance abuse and mental illness within America’s communities.

OraSure Technologies Announces Support for New Federal Oral Fluid Drug Testing Guidelines

BETHLEHEM, Pa., Aug.  19, 2019  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced the sale of its cryosurgical systems business to CryoConcepts, LP for an aggregate purchase price of $12 million in cash.  The transaction includes the transfer of OraSure’s professional Histofreezer® product line and several private label cryosurgical products sold in the consumer market, along with related patents and trademarks, customer contracts and goodwill associated with the business.

News for OraSure Technologies Stock (OSUR)